Key Highlights

  • RFAI shares fell 24.14% pre-market to $44.00, giving back a portion of Friday's 355.62% surge to $58.00.
  • The rally followed Shareholder approval at an extraordinary general meeting of the proposed Business combination with Nanyang Biologics.
  • Nanyang Biologics is expected to begin trading on Nasdaq under the ticker symbol NYB following completion of the deal.
  • RF Acquisition Corp II carries a market Capitalization of approximately $483.94 million following the recent share price volatility.

Shares Pull Back After Historic Rally

RF Acquisition Corp II (NASDAQ:RFAI) shares declined sharply in pre-market trading, retracing a portion of Friday's extraordinary 355.62% rally, which came after shareholders voted to approve the company's proposed business combination with Nanyang Biologics Pte. Ltd., a Singapore-based artificial intelligence drug discovery company.

RF Acquisition Corp II is a Cayman Islands-incorporated blank check company listed on Nasdaq and headquartered in Singapore. Formed in 2024 through a $100 million initial public offering, the company has no substantial operations of its own and is instead focused on identifying and completing a Merger or similar business combination with a target company.

The approved combination with Nanyang Biologics marks a key milestone toward the target company's plan to become a Nasdaq-listed entity under the reserved ticker symbol NYB. Nanyang Biologics applies artificial intelligence to the discovery of novel drug candidates from natural compounds, using a proprietary platform built on a library of more than one million natural compounds designed to identify bioactive candidates that conventional, synthetic-first approaches often overlook.

Volatility Reflects Speculative SPAC Trading Dynamics

RF Acquisition Corp II carries a market capitalization of approximately $483.94 million following the recent volatility, with a trailing price-to-earnings ratio of 511.46. The stock's 52-week range spans $8.94 to $73.00, illustrating the scale of price swings characteristic of special purpose acquisition companies as they approach the completion of a proposed business combination.

The pattern of a sharp rally followed by a partial pullback is common in SPAC trading around key deal milestones, as investors reassess valuation once shareholder approval has been secured but the transaction has not yet formally closed. The business combination remains subject to customary closing conditions before Nanyang Biologics begins trading as an independent Nasdaq-listed company.

What Comes Next for RF Acquisition Corp II

The pre-market pullback in RF Acquisition Corp II shares reflects a natural cooling-off period following an outsized rally tied to shareholder approval of its proposed combination with Nanyang Biologics. Investors will likely watch for confirmation of the deal's closing conditions and the eventual debut of Nanyang Biologics as a standalone Nasdaq-listed company under the ticker NYB.